Single-agent irinotecan as second-line treatment for advanced gastric cancer

Tumori

Volumn 89, Issue 4, 2003, Pages 405-407

  Kanat, Ozkan ^a   Evrensel, Turkkan ^a   Manavoglu, Osman ^a   Demiray, Mutlu ^a   Kurt, Ender ^a   Gonullu, Guzin ^a   Kiyici, Murat ^a   Arslan, Murat ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Gastric cancer; Irinotecan; Second line chemotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; LOPERAMIDE; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; PERITONEUM METASTASIS; STOMACH CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0142137176     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900411     Document Type: Article

References (13)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin, 49: 3-64, 1999.
2. Glimelius B, Hoffman K, Haglund U: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol, 5: 189-190, 1994.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71: 587-591, 1995.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubucin, and methotrexate in advanced gastric cancer. Cancer, 72: 37-41, 1993.
5. Pyrhonen S, Kuitunen T, Kouri M: A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer [abstract]. Ann Oncol, 3 (Suppl): 12, 1992.
6. Scheithauer W, Kornek G, Zeh B: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial (abstract). Second international conference on biology, prevention, and treatment of GI malignancy, Koln, Germany, 68, 1995.
7. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst, 86: 446-449, 1994.
8. Kohne CH, Thuss-Patience N, Catane R, Klein H, Peretz T, Preusser P: Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer [abst 993]. Proc ASCO 18: 258A, 1999.
9. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol, 15: 921-927, 1997.
10. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol, 17: 319-323, 1999.
11. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho, 21: 1033-1038, 1994.
12. Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol, 26: 37-41, 2003.
13. Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG: Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep, 9: 89-92, 2002.